tiprankstipranks
Trending News
More News >
OssDsign AB (SE:OSSD)
:OSSD
Sweden Market

OssDsign AB (OSSD) AI Stock Analysis

Compare
1 Followers

Top Page

SE:OSSD

OssDsign AB

(OSSD)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 5.2)
,
Neutral 47 (OpenAI - 5.2)
,
Neutral 47 (OpenAI - 5.2)
Rating:47Neutral
Price Target:
kr6.00
▼(-46.90% Downside)
Action:ReiteratedDate:02/05/26
The score is primarily held back by persistent losses and ongoing cash burn despite strong revenue growth and very high gross margins, while technicals indicate a pronounced downtrend with weak momentum. Valuation is also constrained by negative earnings and no provided dividend yield.
Positive Factors
High Revenue Growth Momentum
The company shows a durable top-line acceleration with revenue scaling materially and a large step-up in 2025. Sustained double‑digit/rapid revenue growth supports market adoption, creates scale advantages, and increases the probability that fixed costs can be leveraged into sustainable operating profits over months.
Exceptional Gross Margins
Extremely high and improving gross margins reflect strong unit economics and likely low incremental cost to serve. Such structurally attractive margins create long‑term room to absorb operating expenses, enable faster path to profitability as revenue scales, and support durable competitive pricing or margin resilience.
Conservative Balance Sheet / Low Leverage
Very low financial leverage provides a durable capital cushion and reduces refinancing risk, giving management flexibility to fund growth or weather setbacks without immediate liquidity stress. A conservative balance sheet preserves optionality for strategic investments or partnerships over the medium term.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow indicate the business is funding operations with external capital rather than internal cash generation. Over a multi-month horizon this raises financing and dilution risk, constrains reinvestment choices, and makes long‑term viability dependent on either margin conversion or continued access to funding.
Ongoing Operating and Net Losses
Despite strong top-line growth and high gross margins, persistent operating and net losses show the company has not yet converted product economics into sustainable profitability. Continued negative margins risk eroding equity and require durable expense control or higher revenue scale to achieve self‑sustaining profits.
Negative Returns on Equity
Negative ROE signals that invested capital is not generating positive returns and that equity growth has not translated into profitable operations. Over months this can pressure investor confidence and limit ability to raise non‑dilutive capital unless profitability trends reverse and ROE moves into positive territory.

OssDsign AB (OSSD) vs. iShares MSCI Sweden ETF (EWD)

OssDsign AB Business Overview & Revenue Model

Company DescriptionOssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cranial, an implant solution and related accessories for skull defect reconstruction in cranioplasty patients; and OSSDSIGN facial to treat post-traumatic skeletal deformities and congenital skeletal defects. It also offers OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage; and OssDsign Catalyst, a nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.

OssDsign AB Financial Statement Overview

Summary
Revenue growth and exceptionally high/improving gross margins are major positives, and the balance sheet is conservatively financed with minimal leverage. However, operating and net losses persist and cash burn remains significant with negative operating and free cash flow, keeping overall financial performance below average.
Income Statement
46
Neutral
Top-line momentum is strong, with revenue scaling materially over the period and accelerating in 2025 (annual revenue growth of ~208% vs ~19% in 2024). Gross margin is exceptionally high and improving (about 96% in 2025 vs ~75% in 2023), indicating attractive unit economics. However, profitability remains a key weakness: operating losses persist (EBIT margin around -26% in 2025), and the company is still reporting net losses despite improvement versus earlier years (net margin improved from deeply negative levels in 2020–2022 to roughly -28% in 2025). Overall, the business shows strong product-level economics and rapid growth, but has not yet translated this into sustainable profitability.
Balance Sheet
78
Positive
The balance sheet appears conservatively financed with very low leverage, as debt is minimal relative to equity (debt-to-equity roughly 0.6% in 2025, down from ~15% in 2020). Equity has also expanded meaningfully versus earlier years, supporting a stronger capital cushion. The primary concern is that returns on equity remain negative due to ongoing losses (ROE about -16% in 2025, though improved from more negative levels previously), which can pressure equity over time if losses persist. Net-net, financial risk from leverage looks low, but earnings quality must improve to protect the equity base.
Cash Flow
34
Negative
Cash generation remains the biggest weak spot: operating cash flow is consistently negative and worsened in 2025 (about -64m), with free cash flow also negative (about -71m). While the magnitude of cash burn improved versus 2023, the company is still funding operations with external capital rather than internally generated cash. Free cash flow is negative but broadly tracks net losses (free cash flow to net income slightly above 1x in 2024–2025), implying losses are not heavily inflated by non-cash items—yet the core issue remains persistent cash outflows. The setup improves if revenue growth continues while operating spend scales more slowly.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue180.16M133.94M112.16M56.98M31.73M
Gross Profit173.47M127.75M83.64M45.13M20.84M
EBITDA-46.76M-45.31M-122.02M-89.41M-79.97M
Net Income-50.99M-49.66M-130.49M-99.39M-93.92M
Balance Sheet
Total Assets397.87M307.42M356.39M339.50M343.99M
Cash, Cash Equivalents and Short-Term Investments191.35M100.86M165.94M124.65M151.37M
Total Debt1.37M1.97M3.15M13.60M14.13M
Total Liabilities87.84M93.36M105.26M91.39M81.26M
Stockholders Equity310.03M214.06M251.13M248.11M262.72M
Cash Flow
Free Cash Flow-71.43M-63.04M-94.03M-89.36M-89.84M
Operating Cash Flow-64.03M-62.38M-93.91M-89.23M-89.78M
Investing Cash Flow-7.40M-657.00K-124.00K-129.00K-51.85M
Financing Cash Flow163.18M-2.46M135.40M61.84M243.43M

OssDsign AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price11.30
Price Trends
50DMA
7.60
Negative
100DMA
9.57
Negative
200DMA
12.00
Negative
Market Momentum
MACD
-0.40
Negative
RSI
41.36
Neutral
STOCH
83.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Negative. The current price of 11.3 is above the 20-day moving average (MA) of 6.13, above the 50-day MA of 7.60, and below the 200-day MA of 12.00, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 41.36 is Neutral, neither overbought nor oversold. The STOCH value of 83.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:OSSD.

OssDsign AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
kr1.03B-74.03-4.20%21.71%-80.37%
55
Neutral
kr864.43M103.066.93%-5.80%-65.99%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
kr687.03M-5.78-36.55%62.24%21.16%
47
Neutral
kr672.61M-14.0538.43%57.76%
46
Neutral
kr558.95M13.94-2.52%-8.10%62.08%
44
Neutral
kr901.98M-17.24-4.42%13.48%28.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:OSSD
OssDsign AB
6.08
-5.58
-47.86%
SE:PAX
Paxman AB
44.20
-25.60
-36.68%
SE:SEZI
Senzime AB
4.37
-1.01
-18.77%
SE:BACTI.B
Bactiguard Holding AB
15.95
-14.15
-47.01%
SE:CRAD.B
C-Rad AB Class B
25.60
-5.80
-18.47%
SE:SEDANA
Sedana Medical AB
9.08
-1.38
-13.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 05, 2026